Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to cover all solid tumor cancers in which the tumors can be surgically removed. It is on going Phase III trial for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company also offers a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.